HIV-associated visceral leishmaniasis

Clinical Microbiology and Infection

Volumn 7, Issue 6, 2001, Pages 291-300

  Pintado, V ^a,b   Lopez Velez R ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; ANTIRETROVIRUS AGENT; GAMMA INTERFERON; KETOCONAZOLE; PAROMOMYCIN; PENTAMIDINE; PYRROLE DERIVATIVE;

ANEMIA; ANTIBIOTIC PROPHYLAXIS; CARDIOTOXICITY; CELLULAR IMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DRUG CHOICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; IMMUNE DEFICIENCY; NEPHROTOXICITY; OUTCOMES RESEARCH; PANCREATITIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK FACTOR; VISCERAL LEISHMANIASIS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0035382453     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1198-743X.2001.00262.x     Document Type: Review

References (60)

1. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
2. Leishmaniasis
3. Visceral leishmaniasis in immunocompromised hosts
4. Visceral leishmaniasis (Kala-azar) in transplant recipients
5. Leishmania/HIV co-infection, south-western Europe, 1990-1998. Retrospective analysis of 965 cases
6. Leishmania/HIV co-infection. Epidemiological analysis of 692 retrospective cases
7. Report on the consultative meeting on Leishmania/HIV co-infection
8. Clinical manifestations of visceral leishmaniasis associated with HIV infection: A retrospective study of 91 French cases
9. Visceral leishmaniasis and HIV-1 co-infection in southern France
10. Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy
11. Mediterranean leishmaniasis in HIV-infected patients: Epidemiological, clinical, and diagnostic features of 22 cases
12. Visceral leishmaniasis in HIV infection and AIDS: Clinical features and response to therapy
13. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani
14. Visceral leishmaniasis in HIV-infected patients in the south of France
15. Visceral leishmaniasis in HIV infection. A totally opportunistic infection
16. Leishmania and HIV infection: A collaborative study of 228 episodes in a Spanish Mediterranean area
17. Visceral leishmaniasis in HIV-infected and non-HIV-infected patients: A comparative study
18. Clinico-epidemiological characteristics, prognostic factors and survival analysis of patients co-infected with HIV and Leishmania in an area of Madrid, Spain
19. Visceral leishmaniasis in HIV-1-infected individuals: A common opportunistic infection in Spain?
20. Visceral leishmaniasis in patients infected with the human immunodeficiency virus
21. Visceral leishmaniasis in patients infected with human immunodeficiency virus
22. Visceral leishmaniasis in HIV patients: Clinical experience of 8 years
23. Visceral leishmaniasis in patients with HIV infection
24. Visceral leishmaniasis: Comparative study in patients with and without HIV infection
25. Visceral leishmaniasis in HIV-infected patients
26. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV)
27. Leishmania and human immunodeficiency virus coinfection: The first 10 years
28. Treatment of Mediterranean visceral leishmaniasis
29. Visceral leishmaniasis in HIV-positive patients: Primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts
30. Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain
31. HIV-Leishmania coinfections in Italy: Serological data as an indication of the sequence of acquisition of the two infections
32. Leishmania-human immunodeficiency virus coinfection in the Mediterranean basin: Isoenzymatic characterization of 100 isolates of the Leishmania infantum complex
33. Fever of uncertain origin in patients infected with the human immunodeficiency virus
34. Atypical locations of leishmaniasis in HIV-infected patients
35. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients
36. Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus
37. Leishmaniasis in AIDS patients: Results of leukocytoconcentration, a fast biological method of diagnosis
38. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients
39. Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral leishmaniasis in immunocompromised patients
40. The role of serology in the diagnosis and prognosis of visceral leishinamasis in patients coinfected with human immunodeficiency virus type-1
41. Visceral leishmaniasis: Another HIV-associated opportunistic infection? Report of eight cases and review of literature
42. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies
43. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV
44. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
45. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial
46. Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)
47. Visceral leishmaniasis in patients with AIDS. Report of three cases treated with pentavalent antimony and interferon-γ
48. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus
49. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients
50. The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection
51. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: Report of two cases
52. Immunology and treatment of leishmaniases
53. Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania coinfected patients despite treatment
54. HIV viral load and response to antileishmanial chemotherapy in co-infected patients
55. Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART)
56. Highly active antiretroviral therapy (HAART) decreases the incidence of visceral leishmaniasis in HIV-infected subjects
57. Prolonged survival after highly active antiretroviral therapy (HAART) in AIDS-associated visceral leishmaniasis
58. Discontinuation of anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy
59. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy
60. Visceral leishmaniasis in patients coinfected with HIV in the (HAART) era